PFE - Pfizer Inc.
| Previous Close | 43.06 |
| Open | 43.19 |
| Bid | 42.75 x 3000 |
| Ask | 42.77 x 800 |
| Day's Range | 42.77 - 43.21 |
| 52 Week Range | 37.14 - 46.47 |
| Volume | 12,789,924 |
| Avg. Volume | 22,200,879 |
| Market Cap | 237.798B |
| Beta (3Y Monthly) | 0.43 |
| PE Ratio (TTM) | 21.97 |
| EPS (TTM) | 1.95 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | 1.44 (3.34%) |
| Ex-Dividend Date | 2019-08-01 |
| 1y Target Est | 45.75 |
- Yahoo Finance Video•9 days ago
Health Care stocks help lead Wall Street rally
Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani break down what's driving the health care sector higher.
- Motley Fool•2 hours ago
Better Buy: Pfizer vs. AbbVie
Which stock wins in a head-to-head matchup between these two big drugmakers?
- Motley Fool•23 hours ago
8 More Big Pharma Events in 2019 You Don't Want to Miss
These are the clinical trial readouts, FDA decisions, and blockbuster-drug launches that will set the tone for the entire industry.
- Motley Fool•yesterday
3 Stocks to Build Your Portfolio Around
It needs a solid foundation, and Alphabet, Pfizer, and W.P. Carey have proven their worth over time.
- Reuters•2 days ago
UPDATE 2-Health Canada to keep importing Kaleo's epinephrine shot amid shortages
The Canadian health regulator said on Friday it would keep importing U.S.-based Kaleo Inc's epinephrine auto-injectors and expects adequate supply of the devices in the country over the coming months. There has been a shortage of EpiPens in the United States, Europe and Canada, mainly hit by a series of manufacturing delays at Pfizer's Meridian Medical unit that produces all EpiPens sold globally at a single plant near St. Louis. Health Canada's announcement comes after Pfizer Inc, which makes Mylan NV's EpiPen, notified the regulator that a shortage of the 0.3 mg dose of the emergency allergy shots may lead to temporary supply constraints in Canada.
- Zacks•3 days ago
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.
- Zacks•4 days ago
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas
- TipRanks•4 days ago
Sarepta vs Pfizer: Which Stock Should Investors Buy?
Sarepta Therapeutics, Inc. (SRPT) got a major boost in June after Pfizer, Inc. (PFE) presented data on its new Duchenne Muscular Dystrophy (DMD) gene therapy drug at the annual Parent Project Muscular Dystrophy (PPMD) conference. Pfizer’s drug left two patients in the hospital after they experienced severe side effects. Some analysts and financial bloggers believe that these results have SRPT perfectly positioned for sustainable long-term growth. So which stock should investors pick? Sarepta Has the Superior Treatment Sarepta is one of the leading commercial-stage biopharmaceutical companies, specializing in the treatment of rare diseases including DMD. DMD is a genetic disorder primarily affecting boys that causes progressive muscle degeneration and weakness. The company’s data looked stronger than PFE’s not only in terms of safety but also with respect to the level of transparency. Sarepta released Western Blot data showing that its treatment meets the accepted standards for dystrophin quantification, the only measure that’s present in every study. Pfizer on the other hand left this information out. SRPT’s other DMD treatment, Exondys 51, is already on the market and is the only DMD drug of its kind that’s commercially approved. Annual sales for the treatment totaled $301 million, up 95% from last year. As the drug doesn’t have any competition, it’s likely that sales will only continue to grow. This drug alone is expected to generate $400 million in revenues for 2019. The FDA is expected to approve SRPT’s new golodirsen drug for a different subgroup of patients with DMD on August 19. Not to mention the company acquired five new gene therapy candidates for $165 million in February. One of these therapies has already shown promising results for the treatment of Limb-Girdle Muscular Dystrophy. Pfizer Has Been Falling Behind Pfizer was attempting to break into the DMD treatment space, but the findings presented at the PPMD conference were disappointing. In a six-patient study, two different dosages of the gene therapy were given to boys between the ages of 6 to 12 years old. Side effects from the drug put two out of the six boys in the hospital. Experts also said that all measures of expression looked worse than SRPT’s and generally unsafe. This is not the first time the pharmaceutical giant has failed to produce an effective DMD treatment. In August 2018, Pfizer dropped its domagrozumab (PF-06252616) DMD candidate based on poor safety and efficacy test results.The company’s loss of exclusivity for its pain medication, Lyrica, as well as the controversy surrounding drug pricing isn’t helping the situation. Share prices are down 3% year-to-date, with analysts expecting -5% earnings growth for the current quarter. What are the Analysts Saying?With strong results from existing treatments and the possibility of new treatments becoming available, the future is looking bright for SRPT. Morgan Stanley analyst, Matthew Harrison, agrees with that sentiment. On July 9, he reiterated his Buy rating and raised his price target from $165 to $220. “Sarepta's DMD gene therapy is positioned to be the first to market, taking a majority share of the ~$20B prevalent population in the US and expanding internationally with a significant lead. Based on our proprietary analysis we believe investors underappreciate the magnitude of Sarepta’s best-in-class efficacy compared to Pfizer,” he said.On July 1, another top analyst, Brian Abrahams, maintained his Buy rating while increasing the price target from $188 to $220. “Based on our analysis of PFE's initial DMD gene therapy results - incorporating the on-site sentiment from KOLs and patients - we see SRPT as the clear leader in this space and are increasing our out-year DMD share/penetration estimates,” he said. The Takeaway The results are in, and SRPT is the clear winner. The stock boasts a ‘Strong Buy’ analyst consensus, with 12 buy ratings vs just 1 hold over the last three months. The average price target is $215, suggesting 40% upside potential.Click Here to see the full list of SRPT Analyst RatingsAnalysts are not as optimistic about Pfizer. The stock has a ‘Moderate Buy’ analyst consensus and $47 price target, suggesting 9% upside. SRPT & PFE Performance Comparison Details
- Zacks•5 days ago
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
- Zacks•5 days ago
Pfizer (PFE) Gains As Market Dips: What You Should Know
Pfizer (PFE) closed at $42.86 in the latest trading session, marking a +0.25% move from the prior day.
- Zacks•5 days ago
Top Research Reports for Berkshire Hathaway, Pfizer & Danaher
Top Research Reports for Berkshire Hathaway, Pfizer & Danaher
- Simply Wall St.•5 days ago
How Financially Strong Is Pfizer Inc. (NYSE:PFE)?
Investors pursuing a solid, dependable stock investment can often be led to Pfizer Inc. (NYSE:PFE), a large-cap worth...
- Financial Times•5 days ago
The opioid drugs scandal is depressingly familiar
US drug manufacturers and distributors are under the gun. Two decades into the opioid addiction epidemic that has killed more than 200,000 people, the industry is now confronting a cluster of lawsuits and enforcement actions seeking to hold them accountable for a health crisis that adds up to an economic burden of $78.5bn annually. have recently settled with the state of Oklahoma for $270m and $85m respectively.
- InvestorPlace•6 days ago
Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday
A somewhat slack economic report out of China, the world's second-largest economy, stood in the way of stocks notching big gains Monday.Source: Shutterstock China said its second-quarter GDP rose "just" 6.2%, below economists' forecasts calling for 6.3% and good for the country's slowest pace of economic growth in 27 years. Chinese economists are now expecting 2019 growth of 6%, well below the original forecast of 6.5%.Here in the U.S., the Nasdaq Composite rose 0.17% while the S&P 500 added just 0.02%, and the Dow Jones Industrial Average added 0.10%. That after the major domestic benchmarks touched record highs early in Monday's session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCitigroup (NYSE:C) got second-quarter earnings season rolling today, reporting that net income rose to $4.8 billion, or $1.95 per share, from $4.5 billion, or $1.63 per share, a year earlier. Analysts expected per share earnings of $1.80. * 7 Dependable Dividend Stocks to Buy Citi is not a member of the Dow Jones Industrial Average, but the bank's positive earnings surprise could be a sign of things to come. That would be a good thing with Dow components JPMorgan Chase (NYSE:JPM) and Goldman Sachs (NYSE:GS) stepping into the earnings confessional on Tuesday. A Tasty WinnerMcDonald's (NYSE:MCD) posted a modest gain today, but that was enough to extend its year-to-date returns to around 22%, solidifying the burger joint as one of 2019's best-performing members of the Dow. In a note out Monday, Tesley Group reiterated an "outperform" rating on McDonald's while boosting its price target on the stock to $230 from $210. That implies decent upside as Monday closed just above $214.McDonald's shares "offer both offensive and defensive investment attributes for both good times and slower times, and with its menu of both premium and value-priced options," according to Tesley.Piper Jaffray and Wells Fargo also boosted price targets on McDonald's to $226 and $235, respectively. Options ActionMicrosoft (NASDAQ:MSFT), the largest U.S. company by market value, reports earnings on Thursday. It is expected to be a bellwether report given the stock's sheer heft in broad market benchmarks and technology sector funds.Microsoft remains around the vaunted $1 trillion market cap. It appears some options traders are betting on good news from Microsoft's earnings report. At one point on Monday, calls were outpacing puts in the name by a margin of more than 2-to-1, according to Schaeffer's Investment Research. Historically, shares of Microsoft move nearly 3% following the company's earnings reports. Pharma and Politics … AgainThough in modest fashion, the Dow's pharmaceuticals components - Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) - each closed higher today despite drug price commentary from former Vice President Joe Biden, a 2020 Democratic frontrunner.Biden "unveiled a healthcare plan on Monday estimated to cost $750 billion and paid for partly by higher tax rates for the wealthy and doubled tax rates on capital gains," according to Reuters.This is not a "Medicare For All" gambit. Rather, Biden's healthcare proposal is seen as a refresher of Obamacare, which was implemented when he was vice president. Bottom Line for Dow Jones StocksIt's earnings season, meaning it's also complaining season for U.S. companies. Expect one of the primary complaints to be about the strength of the dollar."Of the 5% of S&P 500 companies that have reported so far, more than half of them cited a strong greenback as a headwind to their business in the second quarter, according to FactSet, which parsed through companies' conference call transcripts to look for specific factors weighing on company earnings," reports CNBC.With the Invesco DB US Dollar Index Bullish Fund (NYSEARCA:UUP) up nearly 3% year-to-date, dollar-related earnings commentary gets us back to a familiar theme: the impetus for the Federal Reserve to lower interest rates and do so soon.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential The post Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday appeared first on InvestorPlace.
- Reuters•6 days ago
Biden healthcare plan would curb drug prices, raise taxes on rich
Former U.S. Vice President Joe Biden, the front-runner in the Democratic presidential race, unveiled a healthcare plan on Monday estimated to cost $750 billion and paid for partly by higher tax rates for the wealthy and doubled tax rates on capital gains. "The Biden plan to protect and build on the Affordable Care Act" seeks to strengthen the signature healthcare plan, popularly known as Obamacare, enacted under former Democratic President Barack Obama. Biden was Obama's vice president for eight years.
- Zacks•9 days ago
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
- Zacks•9 days ago
AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.
- Yahoo Finance•9 days ago
Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.
- Zacks•9 days ago
SNY or PFE: Which Is the Better Value Stock Right Now?
SNY vs. PFE: Which Stock Is the Better Value Option?
- Zacks•9 days ago
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
- Reuters•10 days ago
US STOCKS-S&P 500, Dow climb as health insurers, financials gain
The Dow and S&P 500 rose on Thursday to close at record highs as health insurers gained after the Trump administration scrapped a plan designed to rein in prescription drug prices, while financial shares climbed with bond yields. A 5.5% gain in UnitedHealth Group Inc helped the Dow close above 27,000 points for the first time.
- Yahoo Finance•10 days ago
Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
The drug companies provide rebates to PBMs in exchange for distributing their products.
- InvestorPlace•10 days ago
4 Drug Stocks Getting Smashed
U.S. equities were hitting new record highs, with the Dow Jones Industrial Average topping 27,000 for the first time ever while the S&P 500 hits 3,000. The catalyst is an all too familiar one: The promise of more cheap money from the Federal Reserve, with chairman Jerome Powell strongly signaling a rate cut later this month in response to uneven economic data.But the gains are being trimmed in mid-day trading after a strong inflation report suggests the U.S.-China trade spat is starting to have an impact on import prices. And higher inflation would undermine the Fed's desire to lower rates. Stocks, obviously, wouldn't react well to that. * 10 Stocks to Sell for an Economic Slowdown A number of big drug stocks are getting hit amid the pullback on reports the Trump Administration has pulled its plan to eliminate rebates from government drug plans. Had this rule gone through, drug stocks would've been relatively unaffected. Investors now fear the administrations next move to try to lower drug prices. Here are four drug stocks to sell on the news:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (PFE) Click to EnlargePfizer (NYSE:PFE) shares are dropping hard out of a four-month uptrend threatening to cut below both its 50-day and 200-day moving averages. This comes after the stock bonked on resistance from its December high and remains mired in a sideways range that has been in play since last summer.The company will next report results on July 30 before the bell. Analysts are looking for earnings of 75 cents per share on revenues of $13.4 billion. When the company last reported on April 30, earnings of 85 cents per share beat estimates by 10 cents on a 1.6% rise in revenues. Eli Lilly (LLY) Click to EnlargeShares of Eli Lilly (NYSE:LLY) are falling down and out of a four month consolidation range, returning to levels not seen since December. This caps a decline of more than 15% from the highs hit in late March. With the 50-day and 200-day moving averages already lost, watch for a drop down to mid-2018 support near $105, which would be worth a loss of another 4% from here. * 3 Forgotten Tech Stocks Worth Remembering The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.45 per share on revenues of $5.6 billion. When the company last reported on April 30, earnings of $1.33 per share matched expectations on a 2.6% rise in revenues. Merck (MRK) Click to EnlargeMerck (NYSE:MRK) shares are dropping hard and fast away from the two-month consolation range that capped a nice 20% rally off of its 200-day moving average. The stock has gained more than 50% from the lows seen in early 2018 and a ripe for a significant profit taking pullback -- likely resulting in a revisiting of the April lows.The company will next report results on July 30 before the bell. Analysts are looking for earnings of $1.16 per share on revenues of $10.9 billion. When the company last reported on April 30, earnings of $1.22 per share beat estimates by 17 cents on a 7.8% rise in revenues. Bristol-Myers Squibb (BMY) Click to EnlargeShares of Bristol-Myers Squibb (NYSE:BMY) have returned to lows near $44 that have been tested multiple times in a pattern going back to early 2017. The range is rather wide, with prices down more than a third from the highs hit in February 2018. The company is continuing to work with regulators to waylay concerns over its proposed acquisition of Celgene (NASDAQ:CELG). * 10 Best ETFs for 2019: The Race for 1 Intensifies The company will next report results on July 25 before the bell. Analysts are looking for earnings of $1.06 per share on revenues of $6.1 billion. When the company last reported on April 25, earnings of $1.10 beat estimates by two cents on a 14% rise in revenues.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell for an Economic Slowdown * 7 Marijuana Penny Stocks That I May Buy * 7 of The Best Schwab ETFs for Low Fees The post 4 Drug Stocks Getting Smashed appeared first on InvestorPlace.
- Barrons.com•10 days ago
Drug Stocks Are Falling Because Trump’s Next Move on Pricing Could Be Trouble
Investors are worried that the Trump administration’s war to rein in drug prices is just heating up—and that big pharma could be the next target.
- Motley Fool•10 days ago
Here's Why CVS Health Stock Is On the Move Today
A White House proposal that could have lowered drug prices has gone belly up.
